WO2001010896A3 - Factor x analog with an improved ability to be activated - Google Patents

Factor x analog with an improved ability to be activated Download PDF

Info

Publication number
WO2001010896A3
WO2001010896A3 PCT/EP2000/007631 EP0007631W WO0110896A3 WO 2001010896 A3 WO2001010896 A3 WO 2001010896A3 EP 0007631 W EP0007631 W EP 0007631W WO 0110896 A3 WO0110896 A3 WO 0110896A3
Authority
WO
WIPO (PCT)
Prior art keywords
analog
factor
activated
improved ability
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/007631
Other languages
French (fr)
Other versions
WO2001010896A2 (en
Inventor
Michele Himmelspach
Uwe Schlokat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter AG filed Critical Baxter AG
Priority to DE60038312T priority Critical patent/DE60038312T2/en
Priority to EP00949465A priority patent/EP1238065B1/en
Priority to CA002380844A priority patent/CA2380844A1/en
Priority to AU62807/00A priority patent/AU778571B2/en
Priority to DK00949465T priority patent/DK1238065T3/en
Publication of WO2001010896A2 publication Critical patent/WO2001010896A2/en
Anticipated expiration legal-status Critical
Publication of WO2001010896A3 publication Critical patent/WO2001010896A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

This invention describes a factor Xa analog which has a substitution of a minimum of one of the amino acid between Glu226 and Arg234 and possibly Ile235, relative to the amino acid numbering according to Figure 1, a preparation containing the activated form of the factor X analog, and a method for the production of these molecules.
PCT/EP2000/007631 1999-08-10 2000-08-07 Factor x analog with an improved ability to be activated Ceased WO2001010896A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE60038312T DE60038312T2 (en) 1999-08-10 2000-08-07 FACTOR X-ANALOG WITH AN IMPROVED CAPABILITY TO BE ACTIVATED
EP00949465A EP1238065B1 (en) 1999-08-10 2000-08-07 Factor x analog with an improved ability to be actived
CA002380844A CA2380844A1 (en) 1999-08-10 2000-08-07 Factor x analog with an improved ability to be activated
AU62807/00A AU778571B2 (en) 1999-08-10 2000-08-07 Factor X analog with an improved ability to be activated
DK00949465T DK1238065T3 (en) 1999-08-10 2000-08-07 Factor X analog with enhanced activation capability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA1377/99 1999-08-10
AT0137799A AT410216B (en) 1999-08-10 1999-08-10 X-ANALOG FACTOR WITH IMPROVED ACTIVITY

Publications (2)

Publication Number Publication Date
WO2001010896A2 WO2001010896A2 (en) 2001-02-15
WO2001010896A3 true WO2001010896A3 (en) 2002-07-11

Family

ID=3512576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007631 Ceased WO2001010896A2 (en) 1999-08-10 2000-08-07 Factor x analog with an improved ability to be activated

Country Status (9)

Country Link
US (1) US6958322B1 (en)
EP (1) EP1238065B1 (en)
AT (2) AT410216B (en)
AU (1) AU778571B2 (en)
CA (1) CA2380844A1 (en)
DE (1) DE60038312T2 (en)
DK (1) DK1238065T3 (en)
ES (1) ES2302696T3 (en)
WO (1) WO2001010896A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343748B2 (en) 2007-05-22 2013-01-01 Baxter International Inc. Preparative purification process for human furin

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
ATE469216T1 (en) * 2004-08-17 2010-06-15 Csl Behring Gmbh MODIFIED VITAMIN K DEPENDENT POLYPEPTIDES
EP1728798A1 (en) * 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (en) * 2005-11-15 2016-02-05 Philadelphia Children Hospital METHODS AND COMPOSITIONS TO MODULATE HEMOSTASIA.
EP1820508A1 (en) * 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
TWI492951B (en) * 2007-12-31 2015-07-21 Baxter Int Transgenic non-human animals expressing human blood clotting factors and uses thereof
AU2010279463A1 (en) * 2009-08-04 2012-03-01 Baxter Healthcare S.A. Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
JP6514893B2 (en) 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Compositions and methods for modulating hemostasis
MX365612B (en) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof.
EP2950813B1 (en) 2013-01-31 2019-09-04 Pfizer Inc Compositions and methods for counteracting factor xa inhibition
FR3001729B1 (en) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement FACTOR X MUTANTS
MY173548A (en) 2013-09-24 2020-02-04 Pfizer Fxa variant compositions
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
FR3050992A1 (en) * 2016-05-06 2017-11-10 Lab Francais Du Fractionnement FACTOR X MUTANTS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029370A1 (en) * 1993-06-08 1994-12-22 Enzon, Inc. Factor ix - polymeric conjugates
WO1998038317A1 (en) * 1997-02-27 1998-09-03 Baxter Aktiengesellschaft Factor x analogues with a modified protease cleavage site

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT366916B (en) 1980-04-02 1982-05-25 Immuno Ag DEVICE FOR APPLICATING A TISSUE ADHESIVE BASED ON HUMAN OR ANIMAL PROTEINS
US4501731A (en) 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
AT382783B (en) 1985-06-20 1987-04-10 Immuno Ag DEVICE FOR APPLICATING A TISSUE ADHESIVE
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
JP4236698B2 (en) 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー Expression of PACE in host cells and uses thereof
DE4325872C1 (en) 1993-08-02 1994-08-04 Immuno Ag Virus inactivated factor Xa preparation
AT401270B (en) 1994-09-26 1996-07-25 Immuno Ag METHOD FOR QUANTIFYING GENOMIC DNA
AT404838B (en) 1995-11-24 1999-03-25 Immuno Ag PRODUCTION OF PROTEINS FROM PRO-PROTEINS BY FUSION PROTEINS DERIVED FROM FURIN OR FURINANALOGS
AT405517B (en) 1997-02-27 1999-09-27 Immuno Ag FACTOR X-DELETION MUTANTS AND ANALOGS OF THEM

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029370A1 (en) * 1993-06-08 1994-12-22 Enzon, Inc. Factor ix - polymeric conjugates
WO1998038317A1 (en) * 1997-02-27 1998-09-03 Baxter Aktiengesellschaft Factor x analogues with a modified protease cleavage site

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIMMELSPACH, M. ET AL.: "Alteration of the specificity of fX activation by substitution of amino acids constitute its activation site.", THROMBOSIS AND HAEMOSTASIS, vol. Suppl., 1 August 1999 (1999-08-01), pages 758 - Abstr. 2394, XP000982495 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343748B2 (en) 2007-05-22 2013-01-01 Baxter International Inc. Preparative purification process for human furin

Also Published As

Publication number Publication date
AU6280700A (en) 2001-03-05
US6958322B1 (en) 2005-10-25
AT410216B (en) 2003-03-25
EP1238065A2 (en) 2002-09-11
AU778571B2 (en) 2004-12-09
CA2380844A1 (en) 2001-02-15
ATE389013T1 (en) 2008-03-15
DE60038312T2 (en) 2009-03-26
ATA137799A (en) 2002-07-15
EP1238065B1 (en) 2008-03-12
ES2302696T3 (en) 2008-08-01
WO2001010896A2 (en) 2001-02-15
DK1238065T3 (en) 2008-07-07
DE60038312D1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
AU4048299A (en) Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same
WO2001010896A3 (en) Factor x analog with an improved ability to be activated
AU6198700A (en) Process for producing phenyl-alkanes compositions produced therefrom, and uses thereof
AU4143300A (en) Cyclic amide compounds, process for the preparation of the same and uses thereof
DE69928413D1 (en) DEFORMATION STABILIZER, GIPS-CONTAINING MOLDING BODY, METHOD FOR THE PRODUCTION THEREOF, AND PLASMA COMPOSITION USED THEREFOR
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
WO2001047928A3 (en) Imidazo 1,3,5 triazinones and the use thereof
CA2262566A1 (en) Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect
ATE327257T1 (en) SOLID, STABLE AND CONCENTRATED ORTHOCILICAL ACID COMPLEX AND PROCESS FOR THE PRODUCTION THEREOF
AU2002301311A1 (en) Polyacetal resin composition and process for producing the same
WO2001010816A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives
WO2001014493A3 (en) Inorganic coating composition, a method for producing same and the use thereof
AU2002219664A1 (en) Microorganism Producing L-Lysine And Processes For Producing L-Lysine Using The Same
WO2001058875A3 (en) Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives
ZA200202834B (en) Plants having altered amino acid contents and method for the production thereof.
HUP0104942A3 (en) Polycyclic thiazolidin-2-ylidene amines, method for the production and use thereof as medicaments
MXPA02004829A (en) Method for the stereoselective synthesis of cyclic amino acids.
AU3825700A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
CA2376121A1 (en) Stable xylometazoline and oxymetazoline solution
WO2001042250A3 (en) Process for production of diphenyl-dialkoxysilane, phenylalkyl-dialkoxysilane, octaphenylcyclotetrasiloxane and sym-tetraalkyltetraphenyl-cyclotetrasiloxane
AU2003241785A1 (en) Intravenous composition, process for producing the same and preparation thereof
AU4122901A (en) Novel 7,8-dihydro-xanthenone-8-carboxylic acid derivative and novel microbe producing the same
ZA200103191B (en) Vancoresmycin, a process for its production and its use as a pharmaceutical.
ZA200102491B (en) A combined plant coagulate composition, process for the manufacture thereof and uses thereof.
AU5419699A (en) Methoximinophenylacetic acid amides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 62807/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2380844

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000949465

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000949465

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 62807/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000949465

Country of ref document: EP